市值730亿美元、毛利率高达72%的制药巨头GSK plc(LSE/NYSE: GSK)今日宣布,中国国家药品监督管理局已受理Nucala(mepolizumab)用于嗜酸性表型慢性阻塞性肺疾病(COPD)附加治疗的新药申请。 根据InvestingPro分析,GSK保持着强劲的财务状况,连续25年保持盈利和派发股息。此次申请基于第三期MATINEE临床试验结果,该试验显示与安慰...
Learn more about NUCALA (mepolizumab), a maintenance treatment for patients with eosinophilic granulomatosis with polyangiitis (EGPA).
GlaxoSmithKline (GSK). GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps. Press Relase. London, UK: GSK; July 29, 2021. GlaxoSmithKline (GSK). GSK’s Nucala (mepolizumab) receives approval from US FDA. Press Release. London, U...
GSK announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved Nucala, a monoclonal antibody that targets interleukin-5, for the treatment of...